AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17395048 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular (RV) pacing
Number of subjects: 12
Study 17395048 — intervention group
Group type: COMPARATOR
Intervention: No pacing
Number of subjects: 12
Study 16136469 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vCP1452 (10^8.0 TCID50)
Number of subjects: 110
Study 16136469 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-dose vCP1452 (10^7.26 TCID50)
Number of subjects: 110
Study 16136469 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 110
Study 12186798 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week endurance training
Number of subjects: 95
Study 12186798 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 95
Study 10197379 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 2367
Study 10197379 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no prophylaxis
Number of subjects: 2367
Study 7776501 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary vitamin E intake of 100 IU per day or greater
Number of subjects: 156
Study 7776501 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary vitamin E intake within the drug group
Number of subjects: 156
Study 7776501 — intervention group
Group type: COMPARATOR
Intervention: Supplementary vitamin E intake within the placebo group
Number of subjects: 156
Study 7776501 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary vitamin C intake
Number of subjects: 156
Study 7776501 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary intake of vitamin E or vitamin C
Number of subjects: 156
Study 7776501 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of multivitamins
Number of subjects: 156
Study 2336314 — intervention group
Group type: COMPARATOR
Intervention: No needle changes
Number of subjects: 303
Study 2336314 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 needle change
Number of subjects: 303
Study 2336314 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 needle changes
Number of subjects: 303
Study 111945 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g of glucose
Number of subjects: 6
Study 111945 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g of xylose
Number of subjects: 6
Study 111945 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of sodium chloride
Number of subjects: 6
Study 111945 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal administration of small amounts of vasopressin
Number of subjects: 6
Study 111945 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of sodium chloride with beef-meal
Number of subjects: 6
Study 31879124 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster Immunization group (BI) - received a single dose of OCV after 3 years
Number of subjects: 240
Study 31879124 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (Primary Immunization group: PI) - did not receive a booster dose
Number of subjects: 240
Study 31651318 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Surgery (CAS)
Number of subjects: 122
Study 31651318 — intervention group
Group type: COMPARATOR
Intervention: Conventional (manual implantation)
Number of subjects: 122
Study 31651318 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CAS and Conventional)
Number of subjects: 122
Study 28950855 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated testing
Number of subjects: 114
Study 28950855 — intervention group
Group type: COMPARATOR
Intervention: Control group (no repeated testing)
Number of subjects: 114
Study 25667135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol celiac plexus neurolysis (50% ethanol)
Number of subjects: 485
Study 25667135 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline placebo control
Number of subjects: 485
Study 25667135 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection of malignancy
Number of subjects: 485
Study 23376896 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofinity multifocal (MF) contact lens
Number of subjects: 20
Study 23376896 — intervention group
Group type: COMPARATOR
Intervention: Biofinity monovision (MV) contact lens
Number of subjects: 20
Study 21508745 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate fish consumption (three servings per week)
Number of subjects: 0
Study 21508745 — intervention group
Group type: COMPARATOR
Intervention: Fish consumption less than once a month
Number of subjects: 0
Study 21508745 — intervention group
Group type: COMPARATOR
Intervention: Fish consumption more often than less than once a month
Number of subjects: 0
Study 21508745 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte omega-3 levels
Number of subjects: 0
Study 19637104 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 100 mg
Number of subjects: 10
Study 19637104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18041300 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination (VAXIGRIP(R) 2003 Southern hemisphere formulation)
Number of subjects: 527
Study 18041300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study 14713376 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-avoidance goal
Number of subjects: 75
Study 14713376 — intervention group
Group type: COMPARATOR
Intervention: Performance-approach goal
Number of subjects: 75
Study 14713376 — intervention group
Group type: COMPARATOR
Intervention: Mastery goal
Number of subjects: 75
Study 10601064 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance cholangiography (MRC)
Number of subjects: 20
Study 10601064 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiography (ERC)
Number of subjects: 20
Study 9176005 — intervention group
Group type: EXPERIMENTAL
Intervention: Epineural ligatures
Number of subjects: 23
Study 9176005 — intervention group
Group type: EXPERIMENTAL
Intervention: Epineural flaps
Number of subjects: 23
Study 9176005 — intervention group
Group type: EXPERIMENTAL
Intervention: Epineural grafts
Number of subjects: 23
Study 1497476 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation (VT)
Number of subjects: 34
Study 1497476 — intervention group
Group type: EXPERIMENTAL
Intervention: Erotic video (VID)
Number of subjects: 34
Study 1497476 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vibrotactile and erotic video stimulation (VID+VT)
Number of subjects: 34
Study 3545931 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined insulin plus sulfonylurea (gliclazide 40 to 240 mg daily for 12 months)
Number of subjects: 30
Study 3545931 — intervention group
Group type: COMPARATOR
Intervention: Insulin treatment only (control group)
Number of subjects: 30
Study 31470175 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (3 g/day)
Number of subjects: 62
Study 31470175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 30850455 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis (AD)
Number of subjects: 652
Study 30850455 — intervention group
Group type: COMPARATOR
Intervention: Moisturizers with high water: oil ratios (ie, lotions)
Number of subjects: 652
Study 30850455 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizers with low water:oil content (ie, ointments)
Number of subjects: 652
Study 29263340 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroboscopic vision
Number of subjects: 20
Study 29263340 — intervention group
Group type: COMPARATOR
Intervention: Normal vision
Number of subjects: 20
Study 24874588 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant-containing saline solution (group 1)
Number of subjects: 40
Study 24874588 — intervention group
Group type: COMPARATOR
Intervention: Saline without surfactant (group 2)
Number of subjects: 40
Study 23862298 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye health education program (InCHARGE)
Number of subjects: 0
Study 23862298 — intervention group
Group type: COMPARATOR
Intervention: Social-contact control presentation
Number of subjects: 0
Study 21916358 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gel (CG)
Number of subjects: 29
Study 21916358 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine spray (CS)
Number of subjects: 29
Study 21916358 — intervention group
Group type: COMPARATOR
Intervention: placebo gel (PG)
Number of subjects: 29
Study 21916358 — intervention group
Group type: COMPARATOR
Intervention: placebo spray (PS)
Number of subjects: 29
Study 19543665 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-centralization
Number of subjects: 331
Study 19543665 — intervention group
Group type: COMPARATOR
Intervention: Centralization
Number of subjects: 331
Study 16428906 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent myofeedback (feedback provided immediately during the trial)
Number of subjects: 32
Study 16428906 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminal myofeedback (feedback provided delayed after the trial)
Number of subjects: 32
Study 16428906 — intervention group
Group type: COMPARATOR
Intervention: No myofeedback
Number of subjects: 32
Study 15207760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic therapy with etidronate (CTE) - 400 mg/day oral etidronate for 2 weeks followed by 12 weeks of 500 mg/day calcium lactate, repeated every 14 weeks (early-etidronate group)
Number of subjects: 55
Study 15207760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic therapy with etidronate (CTE) - initiated after 18 months of no treatment (late-etidronate group)
Number of subjects: 55
Study 15207760 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 55
Study 11152831 — intervention group
Group type: EXPERIMENTAL
Intervention: MULTI-LINK (ML) stent
Number of subjects: 1040
Study 11152831 — intervention group
Group type: COMPARATOR
Intervention: Palmaz-Schatz (PS) stent
Number of subjects: 1040
Study 9652995 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate, 300 mg, intramuscularly every 3 weeks for 6 months
Number of subjects: 51
Study 9652995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 9652995 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 51
Study 8158680 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial chemotherapy (cisplatin and infusional fluorouracil) followed by loco-regional treatment (group A, n = 118)
Number of subjects: 237
Study 8158680 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial chemotherapy (cisplatin and infusional fluorouracil) followed by loco-regional treatment (group A)
Number of subjects: 237
Study 8158680 — intervention group
Group type: COMPARATOR
Intervention: Loco-regional treatment alone (group B, n = 119)
Number of subjects: 237
Study 8158680 — intervention group
Group type: COMPARATOR
Intervention: Loco-regional treatment alone (group B)
Number of subjects: 237
Study 3045792 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZ) 10-15 mg
Number of subjects: 0
Study 3045792 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (IM) 50 mg and 100 mg
Number of subjects: 0
Study 3045792 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (IM) 50 mg and 100 mg + Diazepam (DZ) 10-15 mg
Number of subjects: 0
Study 30212845 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (two placebo tablets twice a day for 10 days)
Number of subjects: 70
Study 30212845 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 70
Study 27760533 — intervention group
Group type: EXPERIMENTAL
Intervention: TOBY therapy + therapy as usual
Number of subjects: 0
Study 27760533 — intervention group
Group type: COMPARATOR
Intervention: therapy as usual
Number of subjects: 0
Study 24712684 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Number of subjects: 170
Study 24712684 — intervention group
Group type: COMPARATOR
Intervention: Usual physical activity
Number of subjects: 170
Study 23001704 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir 800 mg every 8 hours for 9 days plus a single dose of raltegravir 400 mg on day 10
Number of subjects: 24
Study 23001704 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir 400 mg alone
Number of subjects: 24
Study 21953611 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM with hyperglycemia
Number of subjects: 75
Study 21953611 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM with severe hypoglycemia
Number of subjects: 75
Study 21953611 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic control (NDC) siblings
Number of subjects: 75
Study 19367153 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release carbamazepine capsules (ERCC)
Number of subjects: 0
Study 19367153 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release carbamazepine (IR)
Number of subjects: 0
Study 16995864 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg BIW etanercept for 24 weeks (Study 1)
Number of subjects: 1300
Study 16995864 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg BIW etanercept for 12 weeks (Study 2)
Number of subjects: 1300
Study 16995864 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg BIW etanercept for 12 weeks (Study 2)
Number of subjects: 1300
Study 16995864 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg QW etanercept for 24 weeks (Study 3)
Number of subjects: 1300
Study 16995864 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg BIW etanercept for 24 weeks (Study 3)
Number of subjects: 1300
Study 16995864 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg BIW etanercept for 24 weeks (Study 3)
Number of subjects: 1300
Study 15327681 — intervention group
Group type: EXPERIMENTAL
Intervention: EBM intervention
Number of subjects: 39
Study 11526374 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (6 mg/kg IV)
Number of subjects: 26
Study 11526374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9574353 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 71
Study 9574353 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 71
Study 8489976 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal catheter kept in place for 12 to 24 hours (group 2)
Number of subjects: 87
Study 8489976 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal catheter immediately withdrawn (group 1)
Number of subjects: 87
Study 3284830 — intervention group
Group type: EXPERIMENTAL
Intervention: carbocysteine-sobrerol combination
Number of subjects: 16
Study 3284830 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 29561181 — intervention group
Group type: COMPARATOR
Intervention: Regular day shift (8 h on duty)
Number of subjects: 34
Study 29561181 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous day-night shift (24 h on duty)
Number of subjects: 34
Study 28215346 — intervention group
Group type: EXPERIMENTAL
Intervention: HyFlex EDM (HFEDM)
Number of subjects: 40
Study 28215346 — intervention group
Group type: COMPARATOR
Intervention: ProTaper Next (PTN)
Number of subjects: 40
Study 26233732 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 40mg once daily for 6 months
Number of subjects: 93
Study 26233732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 23438800 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene group (IG) received 30 mL of 0.33% levobupivacaine with adrenalin 1:200,000.
Number of subjects: 68
Study 23438800 — intervention group
Group type: COMPARATOR
Intervention: Selective group (SG) received 15 mL of 0.33% levobupivacaine on each nerve (suprascapular and axillary).
Number of subjects: 68
Study 23438800 — intervention group
Group type: COMPARATOR
Intervention: Selective group (SG)
Number of subjects: 68
Study 23438800 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene group (IG) and Selective group (SG)
Number of subjects: 68
Study 16823591 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 10
Study 16823591 — intervention group
Group type: COMPARATOR
Intervention: Balanced amino acid drink (control)
Number of subjects: 10
Study 12542554 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B‐12 injection treatment
Number of subjects: 140
Study 12542554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 10213011 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 350 mg/m2
Number of subjects: 2
Study 10213011 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 2
Study 10213011 — intervention group
Group type: COMPARATOR
Intervention: Best estimated infusional 5‐FU
Number of subjects: 2
Study 7587606 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 30
Study 7587606 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulant therapy
Number of subjects: 30
Study 1980200 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 15
Study 1980200 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 15
Study 1980200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7428803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin (500 mg)
Number of subjects: 0
Study 7428803 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ampicillin (500 mg)
Number of subjects: 0
Study 29030086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic plates
Number of subjects: 6326
Study 29030086 — intervention group
Group type: COMPARATOR
Intervention: Disposable plates
Number of subjects: 6326
Study 29030086 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblong/rectangular plates
Number of subjects: 6326
Study 29030086 — intervention group
Group type: COMPARATOR
Intervention: Other plate types (colour and sectioning)
Number of subjects: 6326
Study 26963188 — intervention group
Group type: EXPERIMENTAL
Intervention: ERASE-Stress intervention
Number of subjects: 63
Study 26963188 — intervention group
Group type: COMPARATOR
Intervention: Managing Emergencies and Traumatic Incidents (METI) program
Number of subjects: 63
Study 25548079 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weekly intra‐articular injections of hyaluronic acid (HA)
Number of subjects: 196
Study 25548079 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 196
Study 23950640 — intervention group
Group type: EXPERIMENTAL
Intervention: Thai dance group
Number of subjects: 42
Study 23950640 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 20936975 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg laninamivir octanoate
Number of subjects: 1003
Study 20936975 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg laninamivir octanoate
Number of subjects: 1003
Study 20936975 — intervention group
Group type: COMPARATOR
Intervention: oseltamivir (75 mg, administered orally twice daily for 5 days)
Number of subjects: 1003
Study 18779299 — intervention group
Group type: EXPERIMENTAL
Intervention: Flax oil (2.4 g/d)
Number of subjects: 62
Study 18779299 — intervention group
Group type: EXPERIMENTAL
Intervention: Flax oil (3.6 g/d)
Number of subjects: 62
Study 18779299 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (0.6 g/d)
Number of subjects: 62
Study 18779299 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (1.2 g/d)
Number of subjects: 62
Study 18779299 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (1 g/d)
Number of subjects: 62
Study 15950716 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief pain-management programme
Number of subjects: 402
Study 15950716 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy
Number of subjects: 402
Study 12608555 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 11
Study 12608555 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 11
Study 12608555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 11
Study 10703122 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign melanocytic proliferations (Group 1); kappa statistic (k) = 0.76
Number of subjects: 15
Study 10703122 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant melanocytic proliferations (Group 2); kappa statistic (k) = 0.70
Number of subjects: 15
Study 10703122 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate melanocytic proliferations (Group 3); kappa statistic (k) = -0.045
Number of subjects: 15
Study 7477800 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive‐behavioral therapy, nutritional counselling and antidepressant drugs (nortriptyline for 7, fluoxetine for 15)
Number of subjects: 22
Study 1953053 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamicel tent
Number of subjects: 108
Study 1953053 — intervention group
Group type: COMPARATOR
Intervention: Cervagem (1 mg gemeprost pessary)
Number of subjects: 108
Study 6908909 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured teaching about essential hypertension
Number of subjects: 0
Study 6908909 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured teaching)
Number of subjects: 0
Study 30872375 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg THC
Number of subjects: 30
Study 30872375 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg THC
Number of subjects: 30
Study 30872375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28506339 — intervention group
Group type: EXPERIMENTAL
Intervention: AR group with intervention (n=22)
Number of subjects: 96
Study 28506339 — intervention group
Group type: COMPARATOR
Intervention: AR group without intervention (n=22)
Number of subjects: 96
Study 28506339 — intervention group
Group type: COMPARATOR
Intervention: AR group (n=44) and non-AR group (n=20)
Number of subjects: 96
Study 25391252 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day Pycnogenol®
Number of subjects: 93
Study 25391252 — intervention group
Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 93
Study 23392474 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning a new piece of music
Number of subjects: 0
Study 23392474 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0